Med Phys 2019 Nov 01
Management of radiotherapy patients with implanted cardiac pacemakers and defibrillators: A Report of the AAPM TG-203.
Abstract
Managing radiotherapy patients with implanted cardiac devices (implantable cardiac pacemakers and implantable cardioverter-defibrillators) has been a great practical and procedural challenge in radiation oncology practice. Since the publication of the AAPM TG-34 in 1994, large bodies of literature and case reports have been published about different kinds of radiation effects on modern technology implantable cardiac devices and patient management before, during, and after radiotherapy. This task group report provides the framework that analyzes the potential failure modes of these devices and lays out the methodology for patient management in a comprehensive and concise way, in every step of the entire radiotherapy process.
Related Questions
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?
Delivering a high dose rate implies that the pacemaker would be exposed to the machine's direct output. High-dose-rate exposure to a pacemaker could lead to an instantaneous malfunction and, even if temporary, should be avoided. Please err on the safe side.
What radiation dose is a risk for damaging function or active leads from a pacemaker?
This is a complex issue sometimes asked on our weekly OLA/ABR website. According to the updated 2019 AAPM TG-203 report published in Medical Physics by Miften et al., PMID 31571229, and the JACC review by Fradley et al., PMID 34604807, care for patients with CIEDs requires careful attention to indiv...
Do you consider 10MV beams safe in a patient with an implantable cardiac device?
I follow the AAPM TG-203 which considers beams up to 10 MV photons to be non-neutron producing. For example, in a lung, abdominal, or pelvis tumor, I find the reduction in total body dose worthwhile to use 10 MV.